A Multicenter, Randomized, Double-blinded, Positive-controlled Phase III Clinical Trial to Evaluate Lot-to-lot Consistency, Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal meningitis
- Focus Adverse reactions; Pharmacodynamics; Registrational
Most Recent Events
- 03 Apr 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 14 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 06 May 2024 Status changed from not yet recruiting to recruiting.